123 related articles for article (PubMed ID: 35150356)
1. Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors.
Waqar SN; Robinson C; Olszanski AJ; Spira A; Hackmaster M; Lucas L; Sponton L; Jin H; Hering U; Cronier D; Grinberg M; Seithel-Keuth A; Diaz-Padilla I; Berlin J
Invest New Drugs; 2022 Jun; 40(3):596-605. PubMed ID: 35150356
[TBL] [Abstract][Full Text] [Related]
2. A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies.
Zimmermann A; Zenke FT; Chiu LY; Dahmen H; Pehl U; Fuchss T; Grombacher T; Blume B; Vassilev LT; Blaukat A
Mol Cancer Ther; 2022 Jun; 21(6):859-870. PubMed ID: 35405736
[TBL] [Abstract][Full Text] [Related]
3. Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study.
Yap TA; Krebs MG; Postel-Vinay S; El-Khouiery A; Soria JC; Lopez J; Berges A; Cheung SYA; Irurzun-Arana I; Goldwin A; Felicetti B; Jones GN; Lau A; Frewer P; Pierce AJ; Clack G; Stephens C; Smith SA; Dean E; Hollingsworth SJ
Clin Cancer Res; 2021 Oct; 27(19):5213-5224. PubMed ID: 34301752
[TBL] [Abstract][Full Text] [Related]
4. First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors.
Yap TA; Tolcher AW; Plummer R; Mukker JK; Enderlin M; Hicking C; Grombacher T; Locatelli G; Szucs Z; Gounaris I; de Bono JS
Clin Cancer Res; 2024 May; 30(10):2057-2067. PubMed ID: 38407317
[TBL] [Abstract][Full Text] [Related]
5. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.
Bahleda R; Meric-Bernstam F; Goyal L; Tran B; He Y; Yamamiya I; Benhadji KA; Matos I; Arkenau HT
Ann Oncol; 2020 Oct; 31(10):1405-1412. PubMed ID: 32622884
[TBL] [Abstract][Full Text] [Related]
6. A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck Tumors.
Samuels M; Falkenius J; Bar-Ad V; Dunst J; van Triest B; Yachnin J; Rodriguez-Gutierrez A; Kuipers M; You X; Sarholz B; Locatelli G; Becker A; Troost EGC
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):743-756. PubMed ID: 37751793
[TBL] [Abstract][Full Text] [Related]
7. First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
Yap TA; Tan DSP; Terbuch A; Caldwell R; Guo C; Goh BC; Heong V; Haris NRM; Bashir S; Drew Y; Hong DS; Meric-Bernstam F; Wilkinson G; Hreiki J; Wengner AM; Bladt F; Schlicker A; Ludwig M; Zhou Y; Liu L; Bordia S; Plummer R; Lagkadinou E; de Bono JS
Cancer Discov; 2021 Jan; 11(1):80-91. PubMed ID: 32988960
[TBL] [Abstract][Full Text] [Related]
8. Selective ATM inhibition augments radiation-induced inflammatory signaling and cancer cell death.
Chiu LY; Sun Q; Zenke FT; Blaukat A; Vassilev LT
Aging (Albany NY); 2023 Jan; 15(2):492-512. PubMed ID: 36656721
[TBL] [Abstract][Full Text] [Related]
9. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
Falchook GS; Kurzrock R; Amin HM; Xiong W; Fu S; Piha-Paul SA; Janku F; Eskandari G; Catenacci DV; Klevesath M; Bruns R; Stammberger U; Johne A; Bladt F; Friese-Hamim M; Girard P; El Bawab S; Hong DS
Clin Cancer Res; 2020 Mar; 26(6):1237-1246. PubMed ID: 31822497
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
Weiss GJ; Jameson G; Von Hoff DD; Valsasina B; Davite C; Di Giulio C; Fiorentini F; Alzani R; Carpinelli P; Di Sanzo A; Galvani A; Isacchi A; Ramanathan RK
Invest New Drugs; 2018 Feb; 36(1):85-95. PubMed ID: 28726132
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.
Mita M; Fu S; Piha-Paul SA; Janku F; Mita A; Natale R; Guo W; Zhao C; Kurzrock R; Naing A
Invest New Drugs; 2017 Oct; 35(5):616-626. PubMed ID: 28194539
[TBL] [Abstract][Full Text] [Related]
12. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Bendell JC; Rodon J; Burris HA; de Jonge M; Verweij J; Birle D; Demanse D; De Buck SS; Ru QC; Peters M; Goldbrunner M; Baselga J
J Clin Oncol; 2012 Jan; 30(3):282-90. PubMed ID: 22162589
[TBL] [Abstract][Full Text] [Related]
13. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
Gazzah A; Bedard PL; Hierro C; Kang YK; Abdul Razak A; Ryu MH; Demers B; Fagniez N; Henry C; Hospitel M; Soria JC; Tabernero J
Ann Oncol; 2022 Apr; 33(4):416-425. PubMed ID: 35026412
[TBL] [Abstract][Full Text] [Related]
14. A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
Leong S; Moss RA; Bowles DW; Ware JA; Zhou J; Spoerke JM; Lackner MR; Shankar G; Schutzman JL; van der Noll R; Voest EE; Schellens JHM
Oncologist; 2017 Dec; 22(12):1491-1499. PubMed ID: 28798270
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors.
Perez B; Aljumaily R; Marron TU; Shafique MR; Burris H; Iams WT; Chmura SJ; Luke JJ; Edenfield W; Sohal D; Liao X; Boesler C; Machl A; Seebeck J; Becker A; Guenther B; Rodriguez-Gutierrez A; Antonia SJ
ESMO Open; 2024 Feb; 9(2):102217. PubMed ID: 38320431
[TBL] [Abstract][Full Text] [Related]
16. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.
Lin L; Pan H; Li X; Zhao C; Sun J; Hu X; Zhang Y; Wang M; Ren X; Luo X; Shan G; Hui AM; Wu Z; Liu H; Tian L; Shi Y
Lung Cancer; 2022 Apr; 166():98-106. PubMed ID: 35248866
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
[TBL] [Abstract][Full Text] [Related]
19. A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.
Kristeleit R; Plummer R; Jones R; Carter L; Blagden S; Sarker D; Arkenau T; Evans TRJ; Danson S; Symeonides SN; Veal GJ; Klencke BJ; Kowalski MM; Banerji U
Br J Cancer; 2023 Jul; 129(1):38-45. PubMed ID: 37120671
[TBL] [Abstract][Full Text] [Related]
20. A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors.
Mita M; Gordon M; Rejeb N; Gianella-Borradori A; Jego V; Mita A; Sarantopoulos J; Sankhala K; Mendelson D
Target Oncol; 2014 Sep; 9(3):215-24. PubMed ID: 23832397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
